Observational analysis reveals MMR deficiency in 10.7% of atypical hyperplasia cases, indicating its role in endometrial carcinoma risk stratification.
Key Points
MMR deficiency appears confined to atypical endometrial hyperplasia, with 3 of 28 cases showing loss of proteins.
Expression of MLH1 and PMS2 was lost concurrently in the most common pattern of MMR deficiency.
Immunohistochemical analysis revealed retained MMR protein expression in all endometrial hyperplasia cases without atypia.
Identifying abnormal MMR expression may guide genetic counseling for hereditary cancer predisposition.
Cite This Study
Mollova-Kyosebekirova et al. (2025) studied this question.